Statin Safety Report Due Out At Year-End, National Lipid Assoc. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Preliminary results of the National Lipid Association statin safety task force's retrospective study of claims database shows Crestor's incidence of renal events and rhabdomyolysis fall in the middle of the statin class.
You may also be interested in...
AstraZeneca Determined To Validate Crestor Safety, Toprol XL Patent Protection
AstraZeneca is looking to epidemiological data to demonstrate Crestor's safety profile
AstraZeneca Determined To Validate Crestor Safety, Toprol XL Patent Protection
AstraZeneca is looking to epidemiological data to demonstrate Crestor's safety profile
Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen
There is no evidence to suggest Crestor (rosuvastatin) should be withdrawn because of its renal or muscle toxicity profiles, FDA says in its rejection of Public Citizen's petition. "For any degree of LDL-lowering, rosuvastatin is as safe, and may well be safer than, any other marketed statin with regard to muscle toxicity," FDA says.